MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 881 productos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRAS G12C inhibitor 41
CAS:<p>KRAS G12C inhibitor 41 targets a key signaling protein, potentially aiding cancer research.</p>Fórmula:C36H37ClFN9O2Forma y color:SolidPeso molecular:682.19SOS1-IN-4
CAS:<p>SOS1-IN-4 is a potent inhibitor of SOS1 (IC50: 56 nM) and can be used in the study of KRAS-C12C/SOS1 interactions.</p>Fórmula:C24H29F2N4O2PForma y color:SolidPeso molecular:474.48GNE 220
CAS:<p>GNE-220 is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Fórmula:C25H26N8Pureza:98%Forma y color:SolidPeso molecular:438.53ERK1/2 inhibitor 9
CAS:<p>ERK1/2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1/2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates the</p>Fórmula:C31H32ClN7O3Pureza:98%Forma y color:SolidPeso molecular:586.08HPK1-IN-12
CAS:<p>HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Fórmula:C25H24FN5O2Forma y color:SolidPeso molecular:445.49ARS-1323-alkyne
CAS:ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.Fórmula:C28H27ClF2N6O3Pureza:98.00% - 99%Forma y color:SolidPeso molecular:569B-Raf IN 16
CAS:<p>B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.</p>Fórmula:C20H19N5O3SPureza:99.31% - 99.78%Forma y color:SolidPeso molecular:409.46K-Ras G12C-IN-2
CAS:<p>K-Ras G12C-IN-2 is a covalent kras g12c inhibitor.</p>Fórmula:C21H27ClN4O3Pureza:98%Forma y color:SolidPeso molecular:418.92ARS-1323
CAS:<p>ARS-1323 is the racemate of ARS-1620 and a mutant K-ras G12C inhibitor.</p>Fórmula:C21H17ClF2N4O2Pureza:99.53%Forma y color:SolidPeso molecular:430.84KRAS G12C inhibitor 40
CAS:<p>KRAS G12C inhibitor 40 targets KRAS G12C in cancer research (WO2021129824A1, compound 70).</p>Fórmula:C34H36ClFN10O2Forma y color:SolidPeso molecular:671.17TH-Z827
CAS:<p>TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).</p>Fórmula:C30H38N6OPureza:98%Forma y color:SolidPeso molecular:498.66SHP2-IN-22
CAS:<p>SHP2-IN-22, a potent SHP2 allosteric inhibitor, exhibits an IC50 value of 17.7 nM and effectively suppresses proliferation, migration, and invasion in MIA PaCa-</p>Fórmula:C23H22Cl2N8OForma y color:SolidPeso molecular:497.38CHI-000-667
CAS:<p>CHI-000-667 can be used in studies about Ras.</p>Fórmula:C21H16ClNO4SForma y color:SolidPeso molecular:413.87KRAS G12C inhibitor 28
CAS:<p>KRAS G12C Inhibitor 28 is a compound that effectively inhibits the KRAS G12C mutation, exhibiting potent antitumor effects with an inhibitory concentration (</p>Fórmula:C33H36F2N5O4PForma y color:SolidPeso molecular:635.64KRAS G12C inhibitor 49
CAS:<p>KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.</p>Fórmula:C31H31ClN6O3Forma y color:SolidPeso molecular:571.07HPK1 antagonist-1
CAS:<p>HPK1 antagonist-1 (I-792) is an inhibitor targeting HPK1, with potential applications in cancer and immune disease research [1].</p>Fórmula:C28H29FN6O2Forma y color:SolidPeso molecular:500.57ARQ-736
CAS:<p>ARQ 736 effectively targets and inhibits BRAF, crucial in MAPK pathway, beneficial for treating melanomas and certain colon cancers.</p>Fórmula:C25H25N8Na2O8PSForma y color:SolidPeso molecular:674.54Exarafenib
CAS:<p>Exarafenib (RAF/KIN_2787) is an oral pan-RAF inhibitor with antitumor properties, targeting MAPK signaling in cancer research.</p>Fórmula:C26H34F3N5O3Pureza:98.36% - 99.84%Forma y color:SolidPeso molecular:521.58Kras4B G12D-IN-1
CAS:<p>Kras4B G12D-IN-1 is an inhibitor of Kras4B G12D with anticancer activity.Kras4B G12D-IN-1 inhibits Kras protein expression.</p>Fórmula:C16H21ClN2O4SPureza:99.75%Forma y color:SolidPeso molecular:372.87BI-2493
CAS:<p>BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.BI-2493 exhibits antitumor activity and inhibits tumor cell growth.Cost-effective and quality-assured.</p>Fórmula:C24H27N7OSPureza:97.74% - 99.88%Forma y color:SoildPeso molecular:461.58HG6-64-1
CAS:HG6-64-1 (HMSL 10017-101-1, compound 9 (XI-1)) is a potent and selective B-Raf inhibitor with an IC50 = 0.09 μM in B-raf V600E-transformed Ba/F3 cells.Fórmula:C32H34F3N5O2Pureza:99.89%Forma y color:SolidPeso molecular:577.64ZYF0033
CAS:<p>ZYF0033(HPK1-IN-22) is an orally effective inhibitor of HPK1 that inhibits the phosphorylation of MBP proteins and decreases the phosphorylation of SLP76.</p>Fórmula:C26H30N4O2SPureza:99.70%Forma y color:SolidPeso molecular:462.61MK-8353
CAS:<p>MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)</p>Fórmula:C37H41N9O3SPureza:96.15% - 97.19%Forma y color:SolidPeso molecular:691.84Pan-RAS-IN-1
CAS:Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.Fórmula:C36H41Cl2F3N6O2Pureza:99.77%Forma y color:SolidPeso molecular:717.65MK2-IN-4
CAS:<p>MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.</p>Fórmula:C25H24N4O2Forma y color:SolidPeso molecular:412.48KRAS inhibitor-36
CAS:<p>KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.</p>Fórmula:C14H13NO4Forma y color:SolidPeso molecular:259.26AZD4625
<p>AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.</p>Fórmula:C24H21ClF2N4O3Forma y color:SolidPeso molecular:486.9KRAS G12C inhibitor 46
CAS:<p>KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.</p>Fórmula:C32H33F2N7O2Forma y color:SolidPeso molecular:585.65KRASG12C IN-12
CAS:<p>KRASG12C IN-12 (compound-1) acts as an inhibitor of KRASG12C. It forms a ternary complex with intracellular CYPA and the activated mutant of KRASG12C.</p>Fórmula:C29H39N5O6S2Forma y color:SolidPeso molecular:617.78KRAS G12D inhibitor 19
CAS:<p>KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.</p>Fórmula:C35H34F2N6O3Forma y color:SolidPeso molecular:624.68KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Fórmula:C38H32F4N6O3SForma y color:SolidPeso molecular:728.76KRAS ligand 3
CAS:<p>KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].</p>Fórmula:C24H28F3N5Forma y color:SolidPeso molecular:443.51PAT-IN-1
CAS:<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Fórmula:C45H68N4OForma y color:SolidPeso molecular:681.05Calderasib
CAS:<p>Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitors</p>Fórmula:C32H31ClF2N6O4Pureza:98.69%Forma y color:SolidPeso molecular:637.08BBO-8520
CAS:<p>BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.</p>Fórmula:C35H33F6N7O2SPureza:97.879%Forma y color:SolidPeso molecular:729.74KRAS inhibitor-21
CAS:<p>KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.</p>Fórmula:C33H41N5O3Forma y color:SolidPeso molecular:555.71COTI-219
CAS:<p>COTI-219 is an oral inhibitor of KRAS with antitumor properties [1].</p>Fórmula:C17H18N6SForma y color:SolidPeso molecular:338.43pan-KRAS-IN-6
CAS:<p>Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.</p>Fórmula:C29H30ClF3N6O3SForma y color:SolidPeso molecular:635.10Everafenib
<p>Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.</p>Fórmula:C20H23ClFN5O2S2Forma y color:SolidPeso molecular:484.01KRASG12D-IN-3-d3
CAS:KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.Fórmula:C31H27D3ClF6N7O2Forma y color:SoildPeso molecular:685.08Famlasertib
CAS:<p>Famlasertib is a potent inhibitor of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family, capable of penetrating the brain. It exhibits an IC50 value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.</p>Fórmula:C26H27ClN4OForma y color:SolidPeso molecular:446.972G12Si-1
<p>G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.</p>Fórmula:C29H32ClN5O3Forma y color:SolidPeso molecular:534.05TH-Z816
CAS:<p>TH-Z816 acts as a reversible inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 14 µM. This compound is utilized in cancer research [1].</p>Fórmula:C29H38N6OForma y color:SolidPeso molecular:486.65MAP855
CAS:<p>MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.</p>Fórmula:C28H23ClF2N6O3Forma y color:SolidPeso molecular:564.97HPK1-IN-41
CAS:<p>HPK1-IN-41 (compound Z389) functions as an HPK1 inhibitor, exhibiting an IC50 value of 0.21 nM [1].</p>Fórmula:C28H33N5O2Forma y color:SolidPeso molecular:471.59(+)-Perillyl alcohol
CAS:<p>(+)-Perillyl alcohol (0.25-1 mM) inhibits cell growth in SW480 cells. At a concentration of 1 mM and a duration of 24 hours, (+)-Perillyl alcohol increases the number of cells in the G0/G1 phase and reduces the number in the S phase in SW480 cells.</p>Fórmula:C10H16OForma y color:SolidPeso molecular:152.23ZCL279
CAS:<p>ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.</p>Fórmula:C24H18N2O7S2Forma y color:SolidPeso molecular:510.539MBA-m1
CAS:<p>MBA-m1 is an MLKL inhibitor that suppresses necroptosis in Mlkl−/−NIH-3T3 cells. Additionally, MBA-m1 alleviates disease conditions in mouse models of dermatitis and abdominal aortic aneurysm induced by MLKL.</p>Fórmula:C27H21ClN2O2Forma y color:SolidPeso molecular:440.92JNK-1-IN-4
CAS:<p>JNK-1-IN-4 (Compound E1) is an inhibitor of JNK, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7, 19.0, and 9.0 nM, respectively. This compound inhibits the phosphorylation of c-Jun and reduces the expression of TGF-β1-induced EMT markers (such as fibronectin and α-SMA). JNK-1-IN-4 exhibits favorable pharmacokinetic properties with a bioavailability of 69%. Additionally, it demonstrates antifibrotic effects in a Bleomycin-induced mouse model of idiopathic pulmonary fibrosis.</p>Fórmula:C22H25BrN6O3Forma y color:SolidPeso molecular:501.38KRAS G12D inhibitor 28
CAS:<p>KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.</p>Fórmula:C35H32Cl2FN5OForma y color:SolidPeso molecular:628.57
